A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
Key claim: A clinical trial is evaluating whether Gecacitinib Hydrochloride combined with pegylated interferon can achieve hematological remission in polycythemia vera patients over 24 weeks.
Abstract
The goal of this clinical trial is to evaluate the efficacy and safety of Gecacitinib in combination with pegylated interferon for the treatment of polycythemia vera (PV).The main question it aims to answer is:
Can PV patients achieve hematological remission after receiving the combination therapy?
Participants will:
Receive combination treatment with Gecacitinib Hydrochloride Tablets and pegylated interferon for 24 weeks Visit the hospital regularly for examinations and follow-up assessments
Why this matters
PV frontline cytoreduction is being actively re-examined (MITHRIDATE, Givinostat vs HU, Sapablursen), but combination strategies pairing a JAK inhibitor with pegylated interferon have not previously entered clinical evaluation in PV. If tolerable, the Gecacitinib + pegIFN combination could test whether JAK inhibition complements interferon’s molecular response activity, addressing a key gap between symptom/count control and disease modification specific to PV biology.